Seelos Therapeutics Reports Q3 2019 Pipeline Update
08 nov. 2019 07h00 HE
|
Seelos Therapeutics, Inc.
NEW YORK, Nov. 08, 2019 (GLOBE NEWSWIRE) -- Seelos Therapeutics, Inc. (Nasdaq: SEEL), a clinical-stage biopharmaceutical company, today released its third quarter pipeline update. “Seelos continued...
Seelos Therapeutics Announces the Addition of Scott Applebaum as Lead Strategic Regulatory Consultant
15 oct. 2019 09h00 HE
|
Seelos Therapeutics, Inc.
NEW YORK, Oct. 15, 2019 (GLOBE NEWSWIRE) -- Seelos Therapeutics, Inc. (Nasdaq: SEEL), a clinical-stage biopharmaceutical company, today announced the addition of Scott Applebaum to its team as lead...
Seelos Therapeutics to Participate in Upcoming Investor Conference in September
04 sept. 2019 09h00 HE
|
Seelos Therapeutics, Inc.
NEW YORK, Sept. 04, 2019 (GLOBE NEWSWIRE) -- Seelos Therapeutics, Inc. (Nasdaq: SEEL), a clinical-stage biopharmaceutical company, announced today that it will participate in the Oppenheimer Fall...
Seelos Therapeutics Announces Pricing of $6.7 Million Registered Direct Offering
23 août 2019 09h00 HE
|
Seelos Therapeutics, Inc.
NEW YORK, Aug. 23, 2019 (GLOBE NEWSWIRE) -- Seelos Therapeutics, Inc. (Nasdaq: SEEL), a clinical-stage biopharmaceutical company, announced today that it has entered into a securities purchase...
Seelos Therapeutics Reports Q2 2019 Pipeline Update
01 août 2019 09h00 HE
|
Seelos Therapeutics, Inc.
NEW YORK, Aug. 01, 2019 (GLOBE NEWSWIRE) -- Seelos Therapeutics, Inc. (NASDAQ: SEEL), a clinical-stage biopharmaceutical company, today released its second quarter pipeline update. “We have made...
US FDA Grants Orphan Drug Designation for Retrotope’s RT001 in the Treatment of Phospholipase 2G6 (PLA2G6)-Associated Neurodegeneration
02 nov. 2017 09h00 HE
|
Retrotope
LOS ALTOS, Calif., Nov. 02, 2017 (GLOBE NEWSWIRE) -- Retrotope announced today that the U.S. Food and Drug Administration’s (FDA’s) Office of Orphan Products Development (OOPD) granted orphan drug...
Study of Retrotope’s deuterated polyunsaturated fatty acid drugs published in The FEBS Journal
30 oct. 2017 09h00 HE
|
Retrotope
LOS ALTOS, Calif. and TORONTO, Oct. 30, 2017 (GLOBE NEWSWIRE) -- Retrotope and collaborators, led by Dr. Brian Bennett of Queen’s University, have published a paper entitled “Deuterium-reinforced...
Neuronascent Appoints New Board Member
12 avr. 2017 06h30 HE
|
Neuronascent, Inc.
CLARKSVILLE, MD--(Marketwired - April 12, 2017) - Neuronascent, Inc., a neuro-pharmaceutical company developing proprietary therapeutics for Alzheimer's disease, Parkinson's disease, and psychiatric...
SENS Research Foundation Announces New Research Program on Age-Related Neurodegeneration With Buck Institute for Research on Aging
06 févr. 2017 11h00 HE
|
SENS Research Foundation
MOUNTAIN VIEW, CA--(Marketwired - February 06, 2017) - The SENS Research Foundation (SRF) has launched a new research program in collaboration with the Buck Institute for Research on Aging. Dr. Julie...